Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on IQVIA Holdings (IQV – Research Report), Haemonetics (HAE – Research Report) and Denali Therapeutics (DNLI – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IQVIA Holdings (IQV)
BTIG analyst David Larsen maintained a Hold rating on IQVIA Holdings yesterday. The company’s shares closed last Thursday at $180.96, close to its 52-week low of $176.03.
According to TipRanks.com, Larsen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on IQVIA Holdings is a Moderate Buy with an average price target of $260.50, which is a 30.3% upside from current levels. In a report issued on February 4, TipRanks – OpenAI also downgraded the stock to Hold with a $218.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Haemonetics (HAE)
BTIG analyst Marie Thibault reiterated a Buy rating on Haemonetics yesterday and set a price target of $88.00. The company’s shares closed last Thursday at $65.02, close to its 52-week low of $58.80.
According to TipRanks.com, Thibault has 0 stars on 0-5 stars ranking scale with an average return of
Haemonetics has an analyst consensus of Moderate Buy, with a price target consensus of $88.86, implying a 36.7% upside from current levels. In a report issued on January 22, TipRanks – Anthropic also upgraded the stock to Buy with a $78.00 price target.
Denali Therapeutics (DNLI)
BTIG analyst Thomas Shrader maintained a Buy rating on Denali Therapeutics yesterday and set a price target of $32.00. The company’s shares closed last Thursday at $20.02.
According to TipRanks.com, Shrader is a 3-star analyst with an average return of
Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $33.00, which is a 56.0% upside from current levels. In a report issued on January 27, Bank of America Securities also maintained a Buy rating on the stock with a $29.00 price target.
